Zacks Investment Research
27 May 2026, 19:36 UTC · 2h ago
Source · https://www.zacks.com/stock/news/2927848/adma-vs-intellia-therapeutics-which-biotech-stock-is-a-better-pick-now?cid=CS-STOCKNEWSAPI-FT-analyst_blog|most_popular_stocks-2927848
Read source
Search tags
Story key points
3 claims · impact-rated
ADMA Biologics' Bivigam revenues declined 54% year-over-year in the first quarter. — A massive drop in revenue for a core product indicates significant loss of market share or severe pricing pressure.
-0.60ADMA Biologics is experiencing top-line pressure due to increased competition and aggressive pricing in the immunoglobulin (IG) products market. — Systemic competitive pricing pressure suggests a lower margin environment and reduced pricing power for the company.
-0.40ADMA Biologics reported first quarter total revenues of $114.5 million, a 0.3% decrease from the previous year. — Stagnant top-line growth for a small-to-mid-cap biotech is generally viewed negatively by investors seeking growth.
-0.20Ticker attribution
Model heads
The company is facing macro challenges, declining total revenues, and a significant 54% year-over-year drop in Bivigam revenues.
No ticker relationship head found.
Impact vectors
1 dimensions · 9 clusters
Market reaction
0 bid · 0 offered
No stock impact ranking available yet.
No stock impact ranking available yet.
